This weekend in Chicago the American Society of Clinical Oncology hosted its 2019 Annual Meeting, featuring practice-changing research for patients with cancer. Research highlights included updates in lung and breast cancer treatment, as well as new options for predicting responses to novel therapies. MD /alert compiled a list of the top 5 research breakthroughs you may have missed.
RELAY: Combo Ramucirumab/Erlotinib Superior to Erlotinib Alone for EGFR Mutation-Positive NSCLC
Ramucirumab and erlotinib as a first-line treatment for epidermal growth factor receptor mutation-positive non-small lung cancer improved progression-free survival compared with standard-of-care treatment with erlotinib and placebo. READ MORE
Immune-Related Adverse Events Improve Overall Response Rate Following Cancer Immunotherapy
Patients with advanced cancer receiving anti-PD-1 immunotherapy who go on to have an immune-related adverse event may have better overall response rates to treatment than those patients who did not develop an immune-related adverse event. READ MORE
Ribociclib Plus Endocrine Improves Overall Survival for Premenopausal Women with Advanced Breast Cancer
Premenopausal women with hormone receptor–positive or negative advanced breast cancer who received ribociclib in combination with endocrine therapy lived nearly a year longer without disease progression than woman who received endocrine therapy alone. READ MORE
Pembrolizumab Significantly Improves 5-Year Survival for Advanced NSCLC Patients Compared With Chemotherapy
Patients with locally advanced or metastatic non-small cell lung cancer who received first-line therapy with pembrolizumab had a 5-year survival rate of 23.2%. READ MORE
Baseline TGF-β May Predict Response, PFS, OS for HCC Patients Receiving Pembrolizumab
The plasma concentration of transforming growth factor beta (TGF-β) at baseline may help predict response, progression-free survival, and overall survival in patients with hepatocellular carcinoma treated with pembrolizumab as second-line therapy. READ MORE
